The company teaching T cells a new trick - not by replacing their receptor like CAR-T, but by coupling the cancer to the receptor a T cell already has.
Triumvira Immunologics is a clinical-stage immuno-oncology company built around a single, stubborn idea: you may not need to rebuild a T cell to make it fight cancer. Where CAR-T therapy replaces a T cell's receptor with a synthetic one, Triumvira's T cell Antigen Coupler - or TAC - works through the receptor the cell was born with.
The result, the company argues, is a T cell that behaves more like a natural one. Once the TAC molecule binds both the cancer antigen and the endogenous T cell receptor, signaling is carried by the cell's own machinery. Triumvira says that produces a normal immune synapse and lowers the risk of the kind of always-on "tonic" signaling that can drive toxicity in other engineered therapies.
That distinction matters most where cell therapy has struggled hardest: solid tumors. Blood cancers gave CAR-T its first triumphs, but dense, hostile solid tumors have been a wall. Triumvira aimed its whole platform at that wall, with programs against HER2, Claudin 18.2, GPC3 and GUCY2C.
The technology began in an academic lab at McMaster University and grew into an Austin, Texas company backed by roughly $100 million from investors including Leaps by Bayer and Northpond Ventures.
A multi-domain chimeric molecule that couples a cancer antigen to the natural T cell receptor. It is the engine every Triumvira program is built on - designed for both autologous and allogeneic use.
TAC T cell therapy for HER2-positive solid tumors. Early Phase I data showed an 86% disease control rate and 29% overall response rate across dose levels 2-4 in heavily pretreated gastroesophageal cancer.
TAC T cell therapy targeting Claudin 18.2 - one of oncology's hottest solid-tumor antigens - in the company's first-in-human Phase 1/2 trial.
Earlier-stage TAC programs extending the platform to additional tumor-associated antigens, spanning both autologous and off-the-shelf allogeneic strategies.
The ultimate beneficiaries are cancer patients whose solid tumors express antigens like HER2 and Claudin 18.2 - often people who have exhausted standard options. Near term, Triumvira's work runs through oncology investigators, academic cancer centers, and pharmaceutical partners who help test and, potentially, scale the therapy.
The problem is blunt: cell therapy transformed some blood cancers but has largely failed to crack solid tumors, where the tumor microenvironment resists infiltration and engineered cells can lose persistence or trigger toxicity. Triumvira's answer is to make the engineered cell behave more like a natural one.
Triumvira is a venture-backed, clinical-stage biopharmaceutical company. It does not sell a product yet; value is created by advancing proprietary TAC candidates through trials, defending the platform with patents (the TAC technology was granted a U.S. patent in 2019), and forming pharma partnerships and combination studies.
Collaboration to evaluate TAC01-HER2 with KEYTRUDA (pembrolizumab) in HER2-positive solid tumors, governed by a joint development committee.
Manufacturing partner supporting development of Triumvira's autologous TAC T cell therapies.
The TAC technology was invented in the lab of scientific co-founder Dr. Jonathan Bramson before being spun into the company.
Triumvira is co-founded around the TAC technology from McMaster University, with Bloom Burton & Co.
The U.S. Patent and Trademark Office grants a patent covering the T cell Antigen Coupler technology.
Leaps by Bayer and Northpond Ventures lead a $55 million Series A financing.
The Phase I/II trial of autologous TAC01-HER2 in HER2-positive solid tumors begins.
Series A extended to about $100M; a KEYTRUDA combination collaboration with Merck is established.
The first-in-human TACTIC-3 trial of TAC01-CLDN18.2 opens; TACTIC-2 data are shared at ASCO and ESMO.
The company publishes data on the safety and efficacy of TAC T cells targeting Claudin 18.2 in solid tumors.